A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

The drugmaker’s U.S. expansion comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% ...

The site is slated to help produce freeze-dried vaccines such as the company's respiratory syncytial virus launch Arexvy and its shingles vaccine Shingrix. GSK pumps £200M+ into UK manufacturing ...

A global biopharma company just announced that it will be investing up to $800 million to expand its long-time Lancaster ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK expects to begin construction immediately on the project, which includes a new 270,000-square-foot-facility for research and manufacturing ... produced at other sites and employs 380 people.

Additionally, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future ...

GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. The UK ...

Then his mother, Alia Hayes, got some bad news. The manufacturer, GSK, was going to stop manufacturing the brand-name ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Following outlays for sites in the UK and Belgium earlier this year, GSK is planning to invest up to $800m in the US to double the size and capacity of its site in Marietta, Pennsylvania.